Prurigo

• EMA approval · 2026-08-18
  EMA Authorised: Dupixent (dupilumab) — Sanofi Winthrop Industrie

  The EMA has authorised Dupixent (dupilumab) for multiple indications including atopic dermatitis, prurigo, esophageal diseases, asthma, and …

• EMA approval · 2026-03-02
  EMA Authorised: Nemluvio (nemolizumab) — Galderma International

  The European Medicines Agency has authorised nemolizumab (Nemluvio) for use in atopic dermatitis and prurigo, marking a new monoclonal antib…